STAT

Opinion: Peer review could have helped short-circuit the Theranos fake news scandal

Thanks to Theranos, startups might now face a greater burden of proof to demonstrate their technology is effective.
Source: Kristoffer Tripplaar/AP

Theranos had a product almost everyone could get behind: a revolutionary blood test that would allow individuals to quickly and easily access information about their health. Startups like Theranos rely on cutting-edge innovation, then leverage that innovation to attract investors. Now the company’s downfall is a signal to innovators, the public, and the media that we need more transparency and credibility built on peer-reviewed publications.

Holmes, who was accused of falsely claiming that Theranos had developed a portable analyzer that could perform virtually any medical test using with the Security and Exchange Commission for a penalty of $500,000, among other things.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readSociety
Mental Health Care Accounts For A Growing Number Of Private Insurance Claims, Report Finds
Mental health care is accounting for a growing number of private insurance claims, according to a new report.
STAT1 min readWellness
Listen: Drug Pricing Partisanship, Tech’s March Into Health Care, And Tinder For Clinical Trials
Has drug price reform already stalled? How far has tech come in medicine? All that and more on the new episode of our #biotech #podcast, "The Readout LOUD."
STAT4 min readPolitics
In Washington, A Partisan Approach To Lowering Drug Costs Leaves Democrats Doubting Their Own Party Leadership
Even some Democratic lawmakers are questioning Speaker Pelosi’s strategy to couple legislation to lower prescription drug costs with far more contentious Obamacare bills.